Pfizer-Allergan Leadership: Two Dealmakers In The Driver's Seat
This article was originally published in Scrip
Executive Summary
Ian Read will remain CEO of Pfizer Inc. when it mergers with Allergan PLC through a $160bn transaction set to close during the second half of 2016, but Allergan's like-minded CEO Brent Saunders will be sitting beside him as Pfizer PLC's president and chief operating officer – raising questions of whether Saunders is being positioned as Read's eventual replacement.